Key progress in oral Alzheimer's drug: Shanghai Fosun Pharmaceutical (02196) "recalculates" the boundaries of the AD market.

date
09:43 18/11/2026
avatar
GMT Eight
At the CTAD 2026 conference held in Boston, Shanghai Fosun Pharmaceutical (02196) disclosed topline data from the global Phase III POLARIS-AD study of AR1001, an oral Alzheimer's disease (AD) drug candidate that the company has introduced on a regional basis and for which it holds exclusive option rights in core global markets.
At 00:00 Beijing time on November 17, at the CTAD 2026 conference held in Boston, AR1001, an oral candidate drug for Alzheimer's disease (AD) that Shanghai Fosun Pharmaceutical (02196) introduced on a regional basis and for which it holds exclusive option rights in core global markets, disclosed top-line data from the global Phase III POLARIS-AD study: in the monotherapy population, AR1001's primary endpoint, the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), achieved statistical significance, slowing disease progression by 31% compared with the placebo group, while also showing a good safety profile. It is worth noting that the monotherapy population here refers to participants who were not receiving acetylcholinesterase inhibitors or memantine at baseline. For treatment-naive patients with mild Alzheimer's disease, this is undoubtedly a very positive signal. In addition to the statistical significance of the "31% efficacy," the industry is also focused on its route of administrationonce daily, oral. First, look at the gap left by existing therapies. The two currently approved AD disease-modifying drugslecanemab and donanemabare both administered by intravenous infusion. Lecanemab is initially given once every two weeks and can later switch to once every four weeks for maintenance, while donanemab is given once every four weeks; before and after treatment, APOE genotyping, baseline and periodic brain MRI monitoring for ARIA (amyloid-related imaging abnormalities) are required. Public clinical data show that the incidence of ARIA events for marketed antibody drugs ranges from 10% to 30%, with some ApoE4 gene carriers at higher risk. Treatment costs further raise the threshold. Some clinical surveys and health economic estimates show that for early AD patients in China using antibody drugs, drug costs alone are about RMB180,000 per year (based on 60 kg body weight); the annual treatment cost of lecanemab in some markets is close to US$26,500, and when combined with PET screening, MRI monitoring, and infusion services, the full-course cost is a burden on both the healthcare system and families. What antibody drugs address is "whether there is a treatment"; what oral drugs must answer is "whether patients can afford it and stick with it." Industry insiders said that the coverage density of infusion centers, the transportation costs of traveling to and from hospitals, and the time input of family caregivers constitute another "hidden barrier" beyond the commercialization ceiling of antibody drugs. "Oral administration means an early-stage patient living alone can complete once-daily treatment at home, reducing the caregiving pressure on family members." Differences in adherence will vastly different accessibility in the real world. For the 31% slowing data in the monotherapy population, efficacy holds up and intensive monitoring is not requiredaccessibility is precisely the lever that amplifies commercial value. Analysts said the reason accessibility can support the value of a new drug is that it "amplifies" the patient pool. The "China Alzheimer's Disease Report 2026" shows that in 2023 the number of patients with AD and various dementias in China had reached 20.299 million cases, with 3.477 million new cases each year; research released by Chinese scholars at AAIC in 2025 showed that mild cognitive impairment and mild AD together accounted for as much as 52.5%. Recently, some institutions predicted that the AD treatment market will reach the US$10 billion level around 2030. Antibody drugs cover patients who "have infusion conditions, monitoring capacity, and ability to pay," while the broader grassroots and early-stage populations remain outside the door. One quote from a patient's family member has been widely cited: "The patient is fine, but I'm about to collapse." "For Shanghai Fosun Pharmaceutical, what the market needs to recalculate is the size of the entire early AD population and the reach boundary of an oral drug within it," the above-mentioned analyst said.